Redhawk Wealth Advisors Inc. Acquires Shares of 52,416 Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Redhawk Wealth Advisors Inc. purchased a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 52,416 shares of the company's stock, valued at approximately $1,155,000.

Other institutional investors also recently modified their holdings of the company. UMB Bank n.a. lifted its position in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company's stock worth $44,000 after purchasing an additional 2,067 shares during the period. Smithfield Trust Co boosted its position in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company's stock valued at $50,000 after acquiring an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the third quarter valued at $50,000. Claro Advisors LLC acquired a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth about $52,000. Finally, Venturi Wealth Management LLC acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter valued at about $60,000. Institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Stock Down 1.2 %

NYSE TEVA traded down $0.27 during mid-day trading on Thursday, hitting $21.68. The company's stock had a trading volume of 7,199,934 shares, compared to its average volume of 9,598,934. The firm has a market capitalization of $24.56 billion, a price-to-earnings ratio of -25.50, a PEG ratio of 1.06 and a beta of 0.73. The company's 50 day simple moving average is $19.14 and its 200 day simple moving average is $18.16. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries Limited has a twelve month low of $10.83 and a twelve month high of $22.80.

Insider Activity

In related news, Director Roberto Mignone sold 286,000 shares of the firm's stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company's stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Christine Fox sold 19,388 shares of the business's stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares of the company's stock, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 0.55% of the company's stock.

Analysts Set New Price Targets

TEVA has been the subject of a number of research analyst reports. Barclays lifted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an "overweight" rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, October 21st. Finally, StockNews.com cut shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $20.88.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.